Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-306 in IDH1/2-Mutated Glioma
NCT07025018Phase 1Recruiting
- Sponsor
- HUTCHMED
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ranosidenib in glioma (2 arms), sponsored by HUTCHMED. Primary endpoints: Dose Limiting Toxicities at 28 days and Recommended Phase 2 Dose at 24 months. Started Jul 2025; status: recruiting.
02
Drugs
ranosidenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07025018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07025018.